Post-traumatic stress disorder (PTSD) remains one of the most difficult mental health conditions to treat, particularly among military veterans. While conventional therapies help many people, a significant number continue to experience severe symptoms despite years of medication and psychotherapy.
Now, a landmark study from The Ohio State University has provided one of the strongest signals yet that psilocybin-assisted therapy for PTSD could become an important new treatment option. The first U.S. clinical trial investigating psilocybin therapy specifically in veterans with treatment-resistant PTSD found the approach was safeāand the early clinical results exceeded researchers’ expectations.
One month after treatment, 75% of participants no longer met the diagnostic criteria for PTSD.
Published in Communications Medicine, the findings add to the growing body of research exploring psilocibīna terapija for depression, anxiety, addiction and trauma.
Why Researchers Are Studying Psilocybin for PTSD
PTSD affects millions of people worldwide, but veterans are disproportionately affected because of prolonged exposure to combat and traumatic events.
Symptoms can include:
- intrusive memories and flashbacks
- nightmares
- hypervigilance
- emotional numbness
- anger and irritability
- difficulty maintaining relationships
While trauma-focused psychotherapy and antidepressants remain the standard treatments, many veterans continue to experience debilitating symptoms after years of care.
That unmet need is exactly what motivated this study.
As recruitment opened, more than 3,600 veterans expressed interest in participating. After screening 668 applicants, researchers selected 12 veterans with severe, treatment-resistant PTSD ā nine men and three women.
“For a population with severe treatment-resistant PTSD, these results are striking,” said lead author Stacey Armstrong, senior researcher and associate director of Ohio State’s Center for Psychedelic Drug Research and Education (CPDRE).
“While treatments do work for some veterans with PTSD, they’re falling short for many, leaving veterans to continue to search for solutions, which can lead to treatment dropout, long-term disability and elevated suicide risk.“
“It’s this unmet need that inspires us.”
What Does Psilocybin-Assisted Therapy Involve?
Unlike taking psilocibīns recreationally, psilocybin-assisted therapy combines carefully supervised psychedelic sessions with extensive psychotherapy before and after treatment.
Over an 11-week programme, participants completed:
- around eight hours of preparation therapy
- two supervised sessions using 15 mg and 25 mg of synthetic psilocybin
- a further six to eight hours of integration therapy
Preparation sessions help participants build trust with therapists and prepare for difficult emotions that may arise during treatment. IntegrÄcija therapy focuses on making sense of the experience afterwards and translating insights into lasting behavioural change.
This therapeutic framework is increasingly seen as one of the defining features of modern psychedelic medicine.
PTSD Symptoms Improved Dramatically
The results were encouraging across almost every measure. From the beginning of the study to one month after treatment, clinician-rated PTSD symptoms fell by an average of 27.5 points.
Even more remarkably:
- Nine participants showed a clinical response
- Nine participants (75%) entered remission, meaning they no longer met the diagnostic criteria for PTSD
Safety outcomes were equally reassuring.
Researchers reported:
- no serious adverse events
- no increase in suicidal thinking or behaviour
- mild headaches after psilocybin as the most common side effect
Future follow-up papers will examine whether these improvements continue six months after treatment and explore effects on sleep disorders, substance use and biological markers associated with PTSD.
The Therapy May Be Just as Important as the Psilocybin
One of the study’s most interesting findings was that participants began improving before they ever received psilocybin. PTSD symptoms decreased during the preparation therapy alone, before falling much further following the psychedelic sessions.
For researchers, this highlights an important question currently being explored throughout psychedelic medicine.
“There is this big question in the psychedelic therapy field right now about how much of this is a drug effect, how much of this is a therapy effect, and how much is a combination of the two,” explained senior author Alans Deiviss.
The findings suggest that the medicine and psychotherapy work together. Rather than replacing therapy, psilocybin appears to create a temporary state of increased emotional openness, making therapeutic work more accessible.
“This treatment is more than just a drug,” Davis said.
“The drug itself is a catalyst for the deep work that opens a window for people to perhaps access things they wouldn’t be able to access emotionally otherwise, and what that does is catalyze the therapeutic process after.“
“That’s where the magic actually happens. It happens in the therapy, and in the changes that people start to make in their lives after the treatment’s concluded.”
One Veteran’s Journey
Among those who participated was Zachariah Collett, a U.S. Army veteran who served a 28-month combat tour in Iraq. After medically retiring at just 25 years old, Collett lived for years with nightmares, hypervigilance, anger and relentless internal distress.
“I was just absolutely tortured by the internal struggle, the internal dialogue, the noise inside my head and the inability even to just be still,” viÅÅ” teica.
Years of counselling and medication brought little relief. After beginning a broader healing journey through nutrition and integrative therapies, Collett enrolled in the psilocybin trial to continue that process. Now, three years later, he says the treatment changed not only his life but also his family relationships.
“For the first six months to a year, I felt like I had this fantastic set of training wheels while I’m relearning the way to act in situations,” viÅÅ” teica.
“That’s the great thing about this medicine. It’s gentle and it allowed me the space to rediscover, or discover, things I didn’t know I was capable of doing.“
“It allowed me the opportunity to create peace, and stillness, and acceptance, and forgiveness and grace ā all those things opposite of resentment and anger and hatred. It’s rather beautiful.”
A Promising Future for Psilocybin Research
Researchers are careful to point out that this was a small pilot study without a placebo control group, meaning larger randomised clinical trials will be needed to confirm the findings. Still, the results add to an expanding body of evidence suggesting psilocibīna terapija may have enormous potential for people living with treatment-resistant mental health conditions.
For Davis, who has spent more than 16 years studying psychedelic medicine, the field is reaching an exciting turning point.
“This is a very exciting time for psychedelic-assisted therapy research,” viÅÅ” teica.
“These treatments are generally safe, well tolerated and showing a strong signal of efficacy.”
As research continues, psilocybin is increasingly being studied not simply as a medicine that suppresses symptoms, but as a catalyst that may help people safely revisit traumatic memories, process them differently and build new ways of moving forward. For veterans who have exhausted conventional treatment options, that possibility represents something profoundly important: renewed hope.
